July 13, 2018 10:22 AM EDT

Taiho kicks off $130M Arcus deal with drug option; J&J allies with Merck KGaA to take diabetes drug to China

Brittany Meiling

→ Japan’s Taiho Pharma has decided to go for an option to develop and commercialize an adenosine receptor antagonist program from Arcus Biosciences $RCUS, triggering …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Taiho kicks off $130M Arcus deal with drug option; J&J allies with Merck KGaA to take diabetes drug to China

Brittany Meiling

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Tai­ho kicks off $130M Ar­cus deal with drug op­tion; J&J al­lies with Mer­ck KGaA to take di­a­betes drug to Chi­na

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Taiho kicks off $130M Arcus deal with drug option; J&J allies with Merck KGaA to take diabetes drug to China